Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations

BridgeBio presented data at HFSA 2026 showing that acoramidis is associated with an 18% lower composite risk of death and hospitalization compared to tafamidis in a study of 2,684 ATTR-CM patients. The analysis indicated significant reductions in cardiovascular and all-cause hospitalizations, with a 27% lower risk for both cardiovascular and heart failure hospitalizations. These findings support the use of acoramidis as a preferred treatment option for patients with ATTR-CM, emphasizing the importance of hospitalization prevention in this population.